Last reviewed · How we verify

NCT03807856

Treating Acute Pancreatitis With Dabigatran, a Pilot Study

Terminated Phase 1 Last updated 1 September 2022
What this trial tests

Phase 1 trial testing Dabigatran Etexilate Mesylate in Acute Pancreatitis in 2 participants. Terminated before completion.

Timeline
24 June 2019
Primary endpoint
23 July 2020
23 July 2020

Quick facts

Lead sponsorMayo Clinic
PhasePhase 1
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment2
Start date24 June 2019
Primary completion23 July 2020
Estimated completion23 July 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

Adults 18 to 75, any sex, with Acute Pancreatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Researchers are studying the safety and efficacy of Dabigatran in the treatment of acute pancreatitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dabigatran Etexilate Mesylate

Trials testing the same drug.

Other recruiting trials for Acute Pancreatitis

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03807856.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing